gastroesophageal adenocarcinoma

Immune Checkpoint Inhibitors Deliver Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

By MedXY 06/18/2026

MSI-H/dMMR gastroesophageal adenocarcinoma showed high response rates to immune checkpoint inhibitors, including durable complete responses in locoregional disease that may support carefully selected nonoperative management.

Gastroenterology news Oncology

Checkpoint Blockade Delivers Deep, Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

By MedXY 06/18/2026

This single-center cohort found high and durable checkpoint inhibitor responses in dMMR/MSI-H gastroesophageal adenocarcinoma, including complete responses in locoregional disease that may support carefully selected nonoperative management.

Clinical Updates news Oncology Specialties

LEAP-015: Evaluating Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy Alone in Advanced Gastroesophageal Adenocarcinoma

By MedXY 08/07/2025

The LEAP-015 phase III trial found that adding lenvatinib and pembrolizumab to chemotherapy marginally improved progression-free survival but not overall survival in advanced gastroesophageal adenocarcinoma, with increased toxicity.